Contributing Members
Content is delayed by one month. Upgrade your membership to unlock all content. Click for membership options.
Valuation of $5.00
stale
Added 4 years ago
High Risk / High Reward: OPT is a biotechnology company focused on development of new drugs for the treatment of eye diseases. Targeting a huge market OPT has so far done everything right and in my opinion will experience a significant re-rating of it's share price should the trials prove as successful as most anticipate.
Read More